Skip to main content
Bioversys N logo

Bioversys N — Investor Relations & Filings

Ticker · BIOV ISIN · CH0210362643 LEI · 894500UFIGC75NPZEZ68 SW Manufacturing
Open in API
Filings indexed 78 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country CH Switzerland
Listing SW BIOV

About Bioversys N

https://www.bioversys.com/

Bioversys is a clinical-stage biopharmaceutical company focused on the research and development of novel antibacterial therapies to combat the global threat of antimicrobial resistance (AMR). The company develops small molecule drugs that act on novel bacterial targets through innovative modes of action. Its clinical pipeline includes BV100, a treatment for serious hospital infections caused by Acinetobacter baumannii, and Alpibectir, a novel potentiator for multidrug-resistant tuberculosis (MDR-TB). Both candidates are in Phase 2 clinical development. The company's earlier-stage portfolio includes BV200, an anti-virulence compound for Staphylococcus aureus infections, and BV500 for Nontuberculous mycobacteria (NTM) infections, addressing critical unmet medical needs.

Recent filings

Filing Released Lang Actions
BioVersys announces approval of all Board Proposals at Annual General Meeting of Shareholders
Regulatory Filings
2026-04-30 English
BioVersys announces approval of all Board Proposals at Annual General Meeting of Shareholders
Regulatory Filings
2026-04-30 English
BioVersys completes BV100 Phase 1 clinical trial in China
Regulatory Filings Classification · 87% confidence The document is an Ad-hoc announcement under Art. 53 LR published on the SIX Swiss Exchange, providing a clinical development update for BioVersys’s BV100 Phase 1 trial. It is not a financial report (10-K, IR, ER), nor an AGM, proxy, or dividend notice. It does not announce board changes, share issuances, M&A, or legal proceedings. It is a required regulatory disclosure of material company information (fallback category). Therefore, it is classified as a Regulatory Filing (RNS).
2026-04-22 English
BioVersys completes BV100 Phase 1 clinical trial in China
Regulatory Filings Classification · 85% confidence The document is an "ad hoc announcement pursuant to Art. 53 LR" by BioVersys AG about the completion of a Phase 1 clinical trial. It is a regulatory release of market-sensitive information under Swiss Listing Rules rather than a financial report, earnings release, or investor presentation. This falls under the general "Regulatory Filings" category (RNS).
2026-04-22 English
BioVersys Corporate Presentation April 2026
Investor Presentation Classification · 94% confidence The document is a slide-based presentation titled “BioVersys – Proprietary Material” for Q2 2026. It contains forward-looking statements, corporate overview, pipeline details, clinical milestones, market opportunity and strategy. It is clearly an investor‐focused slide deck rather than a formal financial report, earnings release, or regulatory filing. This matches the “Investor Presentation” definition.
2026-04-22 English
BioVersys announces first patient first visit in HABP/VABP pivotal Phase 3 RIV-TARGET trial of BV100
Regulatory Filings Classification · 85% confidence The document is an "Ad hoc announcement pursuant to Art. 53 LR" by BioVersys AG on the SIX Swiss Exchange, providing a corporate update on the start of a pivotal Phase 3 clinical trial. It is not a financial or management report, earnings release, or share transaction notice, nor does it contain AGM materials or voting results. This type of disclosure is a general regulatory announcement under listing rules, falling into the fallback category of Regulatory Filings (RNS).
2026-04-16 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.